Basic information Description References Safety Related Supplier
ChemicalBook >  Product Catalog >  API >  Antibiotics >  Cephalosporins Drugs >  Cefuroxime sodium

Cefuroxime sodium

Basic information Description References Safety Related Supplier
Cefuroxime sodium Basic information
Cefuroxime sodium Chemical Properties
  • Melting point:240-245°C(dec)
  • alpha D20 +60° (c = 0.91 in water)
  • storage temp. Inert atmosphere,2-8°C
  • solubility Freely soluble in water, very slightly soluble in ethanol (96 per cent).
  • form neat
  • pkapKa (water): 2.5; (DMF): 5.1(at 25℃)
  • Water Solubility Freely soluble in water
  • CAS DataBase Reference56238-63-2(CAS DataBase Reference)
Safety Information
Cefuroxime sodium Usage And Synthesis
  • DescriptionCefuroxime sodium is marketed by Eli Lilly and Company under the trade name of Kefurox® and by Glaxo Limited under the trade name of Zinacef®. Cefuroxime sodium is an off-white to white amorphous powder. Cefuroxime sodium is an injectable second generation, semisynthetic, broad spectrum cephalosporin antibiotic with excellent activity in vitro, enhanced stability to many enterobacterial β-lactamases and favorable pharmacokinetic properties.
    It is used to treat a wide variety of bacterial infections. It is effective for treating meningitis, lower respiratory tract infections, urinary tract infections, gonorrhea, septicemia, skin and skin infections, bone and joint infections, and is approved for surgical prophylaxis.
  • References[1] Timothy J. Woznaik and John R. Hicks, Analytical Profile of Cefuroxime Sodium, Analytical Profiles of Drug Substances, 1991, vol. 20, 209-236
    [3] L. M. Galanti, J. D. Hecq, D. Vanbeckbergen and J. Jamart, Long-term stability of cefuroxime and cefazolin sodium in intravenous infusions, Journal of Clinical Pharmacy and Therapeutics, 1996, vol. 21, 185-189
  • Chemical PropertiesWhite Crystalline Solid
  • OriginatorUltroxim,Duncan,Italy,1978
  • UsesCephalosporin antibacterial.
  • Manufacturing ProcessA stirred mixture of N,N-dimethylacetamide (75 ml), acetonitrile (75 ml), triethylamine (42 ml, 0.3 mol) and (6R,7R)-7-amino-3-carbamoyloxy-methylceph-3-em-4-carboxylic acid was immersed in an ice-bath and water (10 ml) was added. The mixture was stirred at 0°C to 2°C for 45 minutes, the solid slowly dissolving to give a yellow solution.
    Meanwhile a stirred suspension of phosphorus pentachloride (14.99 g, 0.072 mol) in dry dichloromethane (150 ml) was cooled to 0°C, and N,N-dimethylacetamide (27.5 ml) was added. The resulting solution was recooled to -10°C and 2-(fur-2-yl)-2-methoxyiminoacetic acid (synisomer) (12.17 g, 0.072 mol) was added. The mixture was stirred at -10°C for 15 minutes and crushed ice (35 g) was added. The mixture was stirred at 0°C for 10minutes, where after the lower dichloromethane phase was added over 10 minutes to the cephalosporin solution prepared above, cooled to -10°C so that the reaction temperature rose steadily to 0°C. The mixture was stirred at 0°C to 2°C for 1 hour, where after the cooling bath was removed and the reaction temperature allowed to rise to 20°C over 1 hour. The reaction mixture was then added slowly to 2 N hydrochloric acid (100 ml) diluted with cold water (1.15 l) at 5°C. The pH of the two phase mixture was adjusted to below 2 with 2 N hydrochloric acid (10 ml), and the mixture was stirred and recooled to 5°C. The solid which precipitated was filtered, washed with dichloromethane (100 ml) and water (250 ml), and dried in vacuo at 40°C overnight to give the title compound (22.04 g, 86.6%).
  • brand nameKefurox (Lilly); Zinacef (GlaxoSmithKline).
  • Therapeutic FunctionAntibiotic
  • Clinical UseCefuroxime (Zinacef) is the first of a series of α-methoximinoacyl–substituted cephalosporins that constitute most of thethird-generation agents available for clinical use. A syn alkoximinosubstituent is associated with β-lactamase stability in these cephalosporins.78 Cefuroxime is classified as a secondgenerationcephalosporin because its spectrum of antibacterialactivity more closely resembles that of cefamandole. It is,however, active against β-lactamase–producing strains thatare resistant to cefamandole, such as E. coli, K. pneumoniae,N. gonorrhoeae, and H. influenzae. Other important Gramnegativepathogens, such as Serratia, indole-positive Proteusspp., P. aeruginosa, and B. fragilis, are resistant.Cefuroxime is distributed throughout the body. It penetratesinflamed meninges in high enough concentrations tobe effective in meningitis caused by susceptible organisms.Three-times-daily dosing is required to maintain effectiveplasma levels for most sensitive organisms, such asNeisseria meningitidis, Streptococcus pneumoniae, and H.influenzae. It has a plasma half-life of 1.4 hours.
Cefuroxime sodium Preparation Products And Raw materials
Cefuroxime sodium (56238-63-2)Related Product Information
Cefuroxime sodium SupplierMore
  • Company Name:Suzhou Langen Biotechnology Co., Ltd. Gold
  • Tel:13921996628
  • Email:380766406@QQ.COM
  • Company Name:Wuhan Huajiu Pharmaceutical Technology Co.,Ltd. Gold
  • Tel:18062681621 027-59225746-
  • Company Name:J & K SCIENTIFIC LTD.
  • Tel:400-666-7788 010-82848833-
  • Company Name:Wuhan Chemwish Technology Co., Ltd
  • Tel:86-027-67849912
  • Company Name:Shanghai Hanhong Scientific Co.,Ltd.
  • Tel:021-54302127 021-54306202-